Roche’s TECENTRIQ in combination with chemotherapy helped people with previously-untreated extensive-stage small cell lung cancer live significantly longer compared to chemotherapy

Basel, 25 June 2018 Roche’s TECENTRIQ in combination with chemotherapy helped people with previously-untreated extensive-stage small cell lung cancer live significantly longer compared to chemotherapy IMpower133 is the first Phase III study with an immunotherapy-based combination to show improvement in overall survival and progression-free survival in the initial treatment of extensive-stage small cell lung cancer... Read more

FDA approves Roche’s Avastin (bevacizumab) plus chemotherapy as a treatment for women with advanced ovarian cancer following initial surgery

Basel, 13 June 2018 FDA approves Roche’s Avastin (bevacizumab) plus chemotherapy as a treatment for women with advanced ovarian cancer following initial surgery Avastin is now approved for ten distinct uses across six different types of cancer in the United States Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the US Food and Drug... Read more

Agilent Companion Diagnostic Gains Expanded FDA Approval in Cervical Cancer

Agilent Companion Diagnostic Gains Expanded FDA Approval in Cervical Cancer PD-L1 IHC 22C3 pharmDx can now be used as an aid to identify cervical cancer patients for treatment with KEYTRUDA® (pembrolizumab) SANTA CLARA, Calif., June 12, 2018 Agilent Technologies Inc. (NYSE: A) today announced that the U.S. Food and Drug Administration (FDA) has approved its... Read more

Merck KGaA, Darmstadt, Germany Provides Update on Tepotinib Phase II Results in Advanced Hepatocellular Carcinoma

Primary endpoints met in two clinical trials for investigational targeted therapy, tepotinib, as a monotherapy in MET-positive, advanced hepatocellular carcinoma (HCC) with Child-Pugh Class A liver function These data provide further evidence of tepotinib activity in patients with MET-positive advanced cancers Given evolving standard of care in HCC, Merck KGaA, Darmstadt, Germany will assess the... Read more

Roche announces FDA approval for Venclexta plus Rituxan for people with previously treated chronic lymphocytic leukaemia

Basel, 11 June 2018 Roche announces FDA approval for Venclexta plus Rituxan for people with previously treated chronic lymphocytic leukaemia Approval based on phase III MURANO study showing Venclexta plus Rituxan reduced risk of disease progression or death by 81% compared to bendamustine plus Rituxan Roche (SIX: RO, ROG; OTCQX: RHHBY), announced today that the... Read more

Roche announces FDA approval for Venclexta plus Rituxan for people with previously treated chronic lymphocytic leukaemia

Basel, 11 June 2018 Roche announces FDA approval for Venclexta plus Rituxan for people with previously treated chronic lymphocytic leukaemia Approval based on phase III MURANO study showing Venclexta plus Rituxan reduced risk of disease progression or death by 81% compared to bendamustine plus Rituxan Roche (SIX: RO, ROG; OTCQX: RHHBY), announced today that the... Read more

Advanced Instruments Announces New Logo

JUNE 7, 2018 • NEWS Advanced Instruments Announces New, Modern Logo Modern font coupled with iconic curve captures company’s legacy and strong focus on innovation NORWOOD, MA- June 7, 2018: Advanced Instruments—a leading developer of scientific and analytical instruments for the clinical, biopharmaceutical, and food-and-beverage industries—unveiled a new, modernized version of its company logo today.... Read more

GE Healthcare FlexFactory Helps XPH Scale Up Industrialization of TCR T-Cell Immunotherapy Drugs

Guangzhou, China & Chalfont, UK — June 7, 2018 — GE Healthcare will provide Xiangxue Pharmaceutical Co., Ltd. (XPH) with a FlexFactory™ for cell therapy, a semi-automated end-to-end manufacturing platform, to help scale up, digitize and accelerate manufacturing processes for their cell therapy clinical trials and future commercialization. This project marks the first-ever application of... Read more

MilliporeSigma Brings Biotechs Closer to Drug Therapy Production and Commercialization

News Release June 5, 2018 Your Contact: Karen Tiano +1 978 495 0093 MilliporeSigma Brings Biotechs Closer to Drug Therapy Production and Commercialization Opens North America’s first BioReliance® End-to-End Biodevelopment Center to help customers with biopharmaceutical manufacturing processes Accelerates clinical development from DNA to market “Advance Biotech Grant Program” expands global biotech commitment to help... Read more

Hamilton Robotics and Waters Corporation Collaborate to Introduce STARWorks for Waters Assay Ready Workstations for Biopharmaceutical Sample Preparation Workflows

Automated, End-to-End Workflows Provide Hands-Free Convenience with Unrivaled Assay Sensitivity and Robust System Performance Reno, Nev., and Milford, Mass. (June 4, 2018) – Hamilton Robotics and Waters Corporation further extend their collaborative goal of streamlining biopharmaceutical sample preparation workflows with the launch of STARWorks for Waters. By integrating liquid handling expertise with in-depth sample preparation... Read more